Antares Pharma, Inc. (ATRS) Receives $3.86 Consensus PT from Analysts

Antares Pharma, Inc. (NASDAQ:ATRS) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $3.86.

Several analysts have weighed in on ATRS shares. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Antares Pharma in a research note on Thursday, February 15th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, April 13th. Finally, ValuEngine upgraded Antares Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

In other news, Director Jacques Gonella sold 200,000 shares of the firm’s stock in a transaction on Friday, May 11th. The stock was sold at an average price of $2.42, for a total value of $484,000.00. Following the completion of the sale, the director now directly owns 11,686,413 shares in the company, valued at $28,281,119.46. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 900,000 shares of company stock valued at $2,233,000 over the last quarter. Corporate insiders own 11.60% of the company’s stock.

Large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Antares Pharma in the fourth quarter valued at $117,000. MetLife Investment Advisors LLC increased its stake in shares of Antares Pharma by 281.1% in the first quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock valued at $158,000 after buying an additional 52,911 shares in the last quarter. Advisor Group Inc. increased its stake in shares of Antares Pharma by 20,267.4% in the fourth quarter. Advisor Group Inc. now owns 101,837 shares of the specialty pharmaceutical company’s stock valued at $203,000 after buying an additional 101,337 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Antares Pharma by 34.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 180,666 shares of the specialty pharmaceutical company’s stock valued at $360,000 after buying an additional 46,766 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Antares Pharma by 533.6% in the first quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after buying an additional 377,824 shares in the last quarter. Institutional investors own 35.74% of the company’s stock.

ATRS stock traded down $0.07 during trading on Thursday, hitting $2.52. 593,850 shares of the company’s stock traded hands, compared to its average volume of 677,130. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.94 and a quick ratio of 2.39. Antares Pharma has a 52 week low of $1.58 and a 52 week high of $4.09. The firm has a market cap of $395.20 million, a price-to-earnings ratio of -22.91 and a beta of 0.19.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Antares Pharma had a negative net margin of 32.96% and a negative return on equity of 52.74%. The business had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.85 million. analysts expect that Antares Pharma will post -0.08 EPS for the current fiscal year.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply